Posts by Sandra Ansanay-Alex
dsm-firmenich invests € 275 Million into Adare Biome
Adare Biome, a unit of Adare Pharma Solutions (CDMO), is a historic player in the development and manufacturing of postbiotic ingredients. The agreement will help the dutch-swiss group dsm-firmenich reinforce its “Health from the Gut” strategy. Tom Sellig, CEO of Adare Pharma Solutions, commented: “As part of our efforts to take Adare Biome…
Read MoreFONGIT Innovation Initiation Program for Life Sciences – and Deep Tech Projects
In 2016 FONGIT, in Geneva, and EPFL Innovation Park launched the Geneus program – the first innovation initiation program – transforming life sciences research into startup projects. After 7 successful years in which 150 innovators were supported, FONGIT has upgraded this program and extended the approach to all areas of deep tech, becoming the FONGIT…
Read MoreAC Immune Receives FDA Fast Track Designation for its Alzheimer’s Vaccine candidate
Lausanne-based biopharmaceutical company AC Immune SA, announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its wholly-owned anti-amyloid beta (Abeta) active immunotherapy (vaccine)-candidate, ACI-24.060, for treatment of Alzheimer’s disease. This follows FDA clearance of the Investigational New Drug (IND) application enabling expansion to the USA of…
Read MoreDéfi Source 2023 rewards 6 innovative projects focusing on people and society
Over 150 innovation and healthcare players attended the presentations of the 12 finalist projects during the finale of the second edition of Défi Source, at the Institut et Haute École de la Santé La Source in Lausanne. 8 prizes were awarded to the most innovative projects. The winning projects The Prix du Jury…
Read MoreDewi, DNAQuraCy, naialabs and MagFlow awarded grants from FIT
The FIT, (Fondation pour l’Innovation Technologique) in canton of Vaud awarded 4 promising Swiss Health Valley projects. DNAQuraCy spun out of UNIL/CHUV and works on the next generation DNA sequencing tools. The three other projects are spin-offs from EPFL: Dewi anticipates anxiety attacks through neuroscience, naialabs allows at-home blood testing and MagFlow is miniaturizing microcatheters.…
Read MoreIsospec Analytics wins CHF 150’000 and Venture Kick’s 3rd round
The startup uses molecular signatures that can be used like bar codes to identify molecules, and developed a technology to measure them in a fast and reliable way, digitizing molecular structure, and greatly simplifying identification processes. This technology is key for the development of precision medicine. The molecular structure of a compound plays…
Read MoreA HUG patient saved by natural viruses called bacteriophages
For the first time, a multidisciplinary team from the University Hospitals of Geneva (HUG) and the University of Geneva (UNIGE) has successfully treated a patient suffering from an antibiotic-resistant chronic bacterial lung infection using bacteriophages. This Swiss first was achieved thanks to a highly personalised, multidisciplinary approach involving the selection of a bacteriophage (a…
Read MoreEBAMed raises EUR 14.35 Million in Series A Funding
The Swiss Health Valley start-up develops a novel image guidance system for the non-invasive treatment of Ventricular Tachycardia through Proton Therapy EBAMed SA, a Geneva-based company specializing in the development of novel image guidance systems for ventricular arrhythmias, announced today the raising of 14.35 M € in Series A Funding to accelerate the…
Read More>>venture>> Startup Competition: Diatheris and ZiZAN!A Biobotanica awarded
Several Swiss Health Valley projects were rewarded during the finale of the >>venture>> Startup Competition on 26 June 2023, at the SwissTech Convention Center. BioSimo : Grand Prize (ZH) Biosimo has been awarded with CHF 150,000 and a McKinsey & Company business consulting package to keep venturing forward successfully. This Zürich-based chemical engineering…
Read MoreDebiopharm invests $6 Million with Benchstrength in Altis Labs
Altis Labs is a Canadian computational imaging company accelerating clinical trials with artificial intelligence. “We are thrilled to partner with Benchstrength and Debiopharm,” said Felix Baldauf-Lenschen, Co-Founder and CEO of Altis. “This partnership will help us execute on our mission to reduce the excessive time and cost it takes to bring novel, effective treatments to patients…
Read More